6 JUNE 2024Bioidentical hormone therapy (BHT) represents an exciting frontier in personalized medicine, captivating attention with its innovative approach. This cutting-edge therapy introduces hormones that are the spitting image of those our bodies produce naturally. What sets BHT apart is its use of hormones crafted from plant sources like soy and yams, making them structurally identical to our own. This precision engineering from nature allows these plant-derived hormones to closely mimic the body's hormonal harmony, offering a promising alternative to the slightly mismatched synthetic hormones.According to Verified Market Reports, the global bioidentical hormone replacement therapy market was valued at USD 7.04 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of 6.6 percent from 2024 to 2030 and reach USD 10.94 billion by 2030.One of BHT's primary appeals lies in its potential to alleviate symptoms associated with hormone imbalance, particularly in menopause and andropause. Proponents argue that bioidentical hormones offer a more personalized approach to hormone replacement therapy (HRT). Tailored dosages and formulations allow for greater precision in addressing each individual's unique hormonal needs, fostering a patient-centered approach to healthcare. Critics, however, raise valid concerns regarding the lack of comprehensive research on BHT's long-term safety and efficacy.This edition of Healthcare Business Review delivers a bird's-eye view of the recent developments in the bioidentical hormone replacement therapy services sector and insights into how organizations align with these trends and adopt lucrative ways to replace outmoded practices.We have curated thought leadership articles from industry experts, including Mike Koroscik, Vice President - Oncology, of Allina Health Cancer Institute, and Roshni Bag, Regional Director of the Oncology Service Line at IU Health, Indianapolis Suburban Region.Our extensive analysis of market trends has allowed us to pinpoint companies at the forefront of innovation in bioidentical hormone replacement therapy services. Among them, Quintessa, Stella Capri Wellness and LowTE Florida® stand out, equipped with groundbreaking technological capabilities poised to transform businesses with unmatched services.We hope this edition of Healthcare Business Review helps you build the partnership you and your organization need to foster an environment driven by efficient technology.Let us know your thoughts!Embracing the Potential of Bioidentical Hormone TherapyEditorialAlex D'souzaManaging Editoreditor@healthcarebusinessreview.comManaging EditorAlex D'souzaEditorial StaffAaron PaulJoe PhillipJames SmithMark RobertVisualizerCopyright © 2024 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.JUNE - 10 - 2024, volume 07 - Issue 18 (ISSN 2836-7030) Published by ValleyMedia, Inc. To subscribe to Healthcare Business ReviewVisit www.healthcarebusinessreview.com Disclaimer : *Some of the Insights are based on our interviews with CIOs and CXOsEmail:sales@healthcarebusinessreview.comeditor@healthcarebusinessreview.commarketing@healthcarebusinessreview.comSamael
< Page 5 | Page 7 >